Coherus BioSciences

About Coherus BioSciences

We are committed to making high-value biosimilars affordable for everyone. It’s an unconventional approach to business that defines who we are and what we do.

At Coherus, we hold ourselves to a higher standard. We don’t break the rules—we write our own.

In early 2021, we expanded our mission into immuno-oncology with a collaboration with Shanghai Junshi Biosciences for the development and commercialization of toripalimab, Junshi Biosciences’ novel anti-PD-1 antibody, in the United States and Canada.

We are embarking on a new phase in our evolution, focused on expanding patient access to important, cost-effective medicines and delivering significant savings to the U.S. healthcare system. Join us, as we seek to break down barriers and make a difference in patients’ lives.

Stock Symbol: CHRS

Stock Exchange: NASDAQ